Abstract 734P
Background
pR-GCT corresponds to the clinical case of retroperitoneal ascertained GCT without radiological evidence of primary testicular tumor and accounts for up to 40 % of extragonadal GCTs. An occult primary testicular tumor is often missed at diagnosis. Treatment modalities and outcomes have not been specifically addressed, preventing robust recommendations. We performed an international call to assess prognosis of treatment outcomes of these patients.
Methods
Clinical, pathological and treatment data pts with pR-GCT between 04/1988 and 01/2022 were retrospectively collected across 4 referral centers. Kaplan Meier methods, univariable and multivariable Cox regression models (MCRMs) were used.
Results
Ninety-nine patients (median age 37 yrs - IQR: 29-45) were collected. Ninety-three (94%) had histological diagnosis by biopsy or primary retroperitoneal lymph-node dissection (RPLND): 60 (62.5%) had non-seminomatous pR-GCTs (pR-NSGCTs) and 33 (34.4%) had seminomatous pR-GCTs (pR-SGCTs). IGCCCG prognostic allocation was possible in 91 pts: 34 (35.8%) were good, 23 (24.2%) intermediate and 34 (35.8%) poor risk, respectively. All pts underwent cisplatin-based chemotherapy, usually BEP regimen (94.9%). After chemotherapy, 25 (25.3%) pts underwent orchiectomy: viable tumor was present in 8 (32%), burn-out lesions in 6 (24%) and no lesion in 11 (44%) cases. After a median follow-up of 45 mos (IQR:15-90), the 5-years OS was 58%, being 85% in case of pR-SGCT and 46% in case of pR-NSGCT. According to IGCCCG classification 5-years OS was 83.3% for good, 57% for intermediate and 42% for poor risk patients, respectively. No difference in term of OS (60% vs 56%, p-value 0.81) was observed between patient who had or not radical orchiectomy. At MCRMs only IGCCCG poor risk category (HR 3.2, CI: 1.18-8.84, p-value 0.02) was independent predictors of a worse OS.
Conclusions
Eventually, a significant proportion of pts with a pR-GCT had a misclassified primary testicular tumor. 5 yrs-OS according to IGCCCG classification is worse than expected. The role of a surgical exploration of the suspected primary tumor remains controversial and the existence of a real category of p-GCT cannot be excluded.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Patrizia Giannatempo.
Funding
Has not received any funding.
Disclosure
P. Giannatempo: Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Astellas, MSD, Merk, Janssen; Financial Interests, Personal and Institutional, Local PI: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17